Institute for Maternal and Child Health - IRCCS Burlo Garofolo, via dell'Istria 65/1, 34137 Trieste, Italy.
Hôpitaux Pédiatriques de Nice, CHU Lenval, 57 Avenue de la Californie, 06200 Nice, France.
Bone. 2020 Jan;130:115144. doi: 10.1016/j.bone.2019.115144. Epub 2019 Nov 6.
Autosomal recessive osteopetrosis (ARO) is a rare congenital disorder of defective bone resorption. The inability of osteoclasts to resorb bone compromises the development of bone marrow cavity, and ultimately, leads to defective hematopoiesis and death within the first decade. The only curative treatment currently available for certain forms of ARO is hematopoietic stem cell transplantation (HSCT). Infants over ten months of age suffering from ARO are defined as patients with advanced disease; HSCT to these patients is associated with high risk of transplant-related mortality (TRM). Because of the extreme variability of ARO clinical phenotypes, the most reliable predictive factor of TRM and graft failure risk is the residual bone marrow space volume.
We report clinical and radiological outcomes of one patient affected by ARO and treated with HSCT at advance stage of the disease. We describe the anomalies in various tissues, including bone marrow and bones at the moment of the diagnosis and document their gradual disappearance after HSCT until their complete resolution based on magnetic resonance imaging (MRI) observations. We provided radiological images of the cranial vault bone structure modifications, correlating the radiological appearance of the optical canals and nerves and of the cerebellum with the neurological manifestations of the disease.
Our results demonstrate that MRI is a highly sensitive technique that provides excellent images of bone marrow space before and after HSCT without exposing children to ionizing radiation. MRI also permits us to evaluate post-transplant skeletal remodeling and the deriving changes in the hematopoietic and sensory system.
常染色体隐性骨硬化症(ARO)是一种罕见的先天性骨吸收缺陷疾病。破骨细胞无法吸收骨骼,会影响骨髓腔的发育,最终导致造血功能缺陷,并在 10 年内死亡。目前,对于某些形式的 ARO,唯一可行的根治性治疗方法是造血干细胞移植(HSCT)。10 个月以上患有 ARO 的婴儿被定义为晚期疾病患者;这些患者接受 HSCT 与移植相关死亡率(TRM)高相关。由于 ARO 临床表型的极端可变性,TRM 和移植物失败风险的最可靠预测因素是残余骨髓空间体积。
我们报告了一例患有 ARO 的患者的临床和放射学结果,该患者在疾病的晚期接受了 HSCT 治疗。我们描述了诊断时各种组织(包括骨髓和骨骼)的异常,并通过磁共振成像(MRI)观察记录了它们在 HSCT 后的逐渐消失,直到完全消失。我们提供了颅骨骨结构改变的放射图像,将视神经管和神经以及小脑的放射表现与疾病的神经表现相关联。
我们的结果表明,MRI 是一种高度敏感的技术,可在不使儿童暴露于电离辐射的情况下提供 HSCT 前后骨髓空间的出色图像。MRI 还使我们能够评估移植后的骨骼重塑以及造血和感觉系统的后续变化。